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Background: In July 2005, Argentina was the first country after the United States to adopt the MELD
system. The purpose of the present study was to analyse the impact of this new system on the adult liver
waiting list (WL).
Methods: Between 2005 and 2009, 1773 adult patients were listed for liver transplantation: 150 emer-
gencies and 1623 electives. Elective patients were categorized using the MELD system. A prospective
database was used to analyse mortality and probability to be transplanted (PTBT) on the WL.
Results: The waiting time increased inversely with the MELD score and PTBT positively correlated with
MELD score. With scores  18 the PTBT remained over 50%. However, the largest MELD subgroup with
<10 points (n = 433) had the lower PTBT (3%). In contrast, patients with T2 hepatocellular carcinoma
benefited excessively with the highest PTBT (84.2%) and the lowest mortality rate (5.4%). The WL
mortality increased after MELD adoption (10% vs. 14.8% vs. P < 0.01). Patients with <10 MELD points
had >fourfold probability of dying on the WL than PTBT (14.3% vs. 3%; P < 0.0001).
Conclusions: After MELD implementation, WL mortality increased and most patients who died had a
low MELD score. A comprehensive revision of the MELD system must be performed to include cultural
and socio-economical variables that could affect each country individually.
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Introduction
At present, there is consensus that a liver allocation policy should
use objective medical criteria to prioritize waiting candidates
based on the severity of liver disease. Since February 2002, the
allocation of grafts for liver transplantation (LT) from cadaveric
donors in the US has been based on medical urgency, which is
estimated according to the model for end-stage liver disease
(MELD) score.1 MELD is an objective score based on pre-
transplantation laboratory data, including serum creatinine level,
total bilirubin level and international normalized ratio (INR). The
MELD-based allocation policy was designed prospectively using
validated predictive models and employing a continuous scale in
contrast to the previous subjective system.2–4
In the US, the change in the allocation system from a waiting
time-based system to a risk-based system using the MELD score
has lowered pre-transplant mortality, without adversely impact-
ing post-transplant survival despite increased severity of illness at
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the time of transplantation.1 Clearly, the new allocation system
has been scrutinized more closely and rigorously than any other
method for liver allocation.5 Although this interest has been wide-
spread throughout the world, few countries have adopted the
system. To date, the MELD-based allocation system created and
initiated in the US lacks international validation.
In Argentina, the first LT was performed in 1988. Initially, as in
most countries, liver allocation policy was based on patient’s loca-
tion of care and time on the waiting list. Before 2005, two catego-
ries existed: emergency and non-emergency patients. Among the
non-emergency patients, those requiring continuous intensive
care received first priority (i.e. Urgency A), organ allocation was
prioritized next to patients requiring continuous hospitalization
(i.e. Urgency B), and finally to patients who were cared for at
home (i.e. Electives). Among each category, as the waiting list
continued to grow, waiting time became a major factor in deter-
mining who received a donor organ. In July 2005, Argentina was
the first country that followed the US in adopting the MELD-
based allocation system for patients requiring LT. Although more
than two decades of LT history have passed, only case reports or a
few partial single-centre experiences have been reported in the
English literature from Argentina.6–14
With the intention to validate internationally the new allocation
system using a large cohort of LT candidates, we analysed a con-
secutive series of patients listed for LT in Argentina for almost 4
years under the MELD system. This is the first report in the
literature using a large national cohort of patients from a prospec-
tively collected official database from the INCUCAI (Instituto
Nacional Central Unico Coordinador de Ablacion e Implante) that
represents the National Institute for organ allocation in Argentina.
Materials and methods
In July 2005, all liver transplant candidates listed in Argentina
were re-categorized under the MELD-based allocation system.
With the aim to assess the impact of the new allocation system on
the waiting list of LT candidates, data referred to a cohort of
consecutive adult patients (i.e.18 years) listed between July 2005
and April 2009 who were analysed using a prospective collected
national database.
All patients were grouped in two categories: emergency and
non-emergency or elective. Emergency status included fulminant
liver failure, primary non-failure of the graft or vascular compli-
cation after LT leading to the need of re-transplantation in the first
7 postoperative days. In the pre-MELD era, the elective category
included all patients listed under the status Urgency A, Urgency B
or Electives. After the MELD system implementation, each non-
emergency patient was stratified according to the MELD score
calculation and defined as elective. For patients in whom the
MELD score was thought to estimate inaccurately their need of LT,
each centre could make a request to an Experts Committee. for
priority points A specific regulation including three entities for
upgrading of the MELD score including familial amyloidotic
polyneuropathy (16 points), hepatopulmonary syndrome (20
points) and T2 hepatocellular carcinoma (HCC) defined as 1
tumour 2–5 cm or 2 or 3 tumors < 3 cm in diameter according to
pre-operative imaging (22 points).15 Similar to US practice,
patients with a MELD score of 22 as a result of the pre-transplant
diagnosis of T2 HCC received an additional point for every 3
months on the waiting list.
For other conditions for which the need for LT was not
defined accurately by the MELD score, each centre could also
request additional points. Each non-established category in the
regulation was considered individually by the Experts Commit-
tee to determine the appropriateness of the requested increase in
priority on the basis of medical evidence from the literature or
expert opinions.
During the MELD era, several adult candidates variables were
analysed including age, gender, aetiology of liver disease, MELD
score (i.e. score registered at the time of LT, drop-out, death or the
most recent), waiting list time, status on the waiting list (emergency
or non-emergency) and reasons for removal of the waiting list. For
the global analysis of the cohort of patients, the MELD score
calculation included additional points given as MELD exceptions.
Elective candidates were grouped according to the MELD
points on the list as follows: <10, 10–13, 14–17, 18–21, 22–25,
26–29, 30–33, 34–37 and >37, to analyse intergroup variation of
studied variables. To properly assess accessibility to cadaveric
donor LT and mortality rate on the waiting list for each subgroup
of MELD points regardless of the decision of the Experts Com-
mittee, all patients with additional priority MELD points were
excluded and analysed separately.
To analyse the impact of the MELD system adoption on mor-
tality rate on the waiting list for LT, many variables related to
organ donation and transplantation activity were revised using
the official registry at the INCUCAI. Since 2004 (i.e. first year
before MELD adoption) analysis included: number of live and
cadaveric donor LT, status on the waiting list (emergency or non-
emergency), annual total and multi-organic donation rate, deaths
and number of patients on the waiting list. Using the official
national registry, the number of centres performing adult LT and
its activity was also revised.16
Statistical analysis
Summary data are presented as median (range) or interquartile
range. Differences between groups were tested using the c2-test for
categorical and Mann–Whitney U-test for continuous variables.
All tests were performed two-tailed. Statistical significance was
indicated by P-values of less than 0.05. Calculations were under-
taken with SPSS statistical software package (version 13.0; SPSS
Inc., Chicago, IL, USA).
Results
Donation rate, waiting list and transplantation activity
in Argentina
The national overall donation rate [from 10.5 donors per million
in population (PMP) to 13.1] and the multi-organic donation rate
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(5.4 to 7.6 donors PMP) had a continuous increment from 2004 to
2008. However, a great variation in the national overall donation
rate was documented among 24 regions or provinces in our
country ranging from as high as 34.5 PMP in Corrientes to as low
as zero in Santiago del Estero and San Luis.
During the study period, a cohort of 1773 adult patients was
listed for LT in Argentina. The total number of patients on the
waiting list and the number of LT had a continuous increment
reaching 485 patients on the national waiting list and 271 cadav-
eric donor LT, respectively, during 2008 (Fig. 1). To assess the
magnitude of the gap between the number of patients on the
waiting list and the number of deceased donor LT, the ratio of
deceased donor LT/number of patients on the waiting list was
used. This ratio increased constantly with time from 0.46 in 2002,
0.48 in 2004 and peak of 0.55 in 2008 demonstrating that the
increment was higher in the number of transplants compared
with the number of patients included on the waiting list. Inversely,
the number of live donor LT continuously decreased in the same
period which is unusual in the last years. The overall access of
elective adult candidates to cadaveric LT was 41% and less than
1% to live donor LT.
A total of 760 adult LT (rate per year: 202) were performed in
this 45-month period: 665 in elective and 95 in emergency candi-
dates. The number of accredited centres to perform LT at the end
of 2008 was 18. However, when the number of LT was analysed
individually in each centre during 2008, dissimilar activity was
observed: 2 centres with no transplant activity, 9 centres with <10
transplants, 4 with 10–20 and only 5 centres performed > 20
transplants in 2008.
Characteristics of elective adult patients listed for LT
In the study period, among all adult candidates included in the
national liver waiting list, 150 (28%) were under emergency and
1623 (72%) under elective status (Table 1). Patients listed under
elective status were older and more frequently male when com-
pared with emergency candidates. The most frequent underlying
liver disorder in elective candidates was hepatitis C infection-
related cirrhosis (25.4%) followed by alcoholic cirrhosis (18.7%),
cryptogenic cirrhosis (13.1%), autoimmune hepatitis (9.9%),
primary biliary cirrhosis (7.5%) and metabolic cirrhosis (3.2%).
The median MELD score of elective patients was 33 (range:
6–48). In this cohort, it was observed that 141/1623 (8.6%)
patients had upgraded MELD scores as a result of extra-points
provided according to the following entities: 2 familial amy-
loidotic polyneuropathy, 6 hepatopulmonary syndrome, 111 T2
HCC and 22 other reasons not included in the official national
regulation.
When stratified in subgroups according to the MELD scores,
the number of cadaveric LT for elective candidates was mainly
centralized in the subgroup with 22–25 MELD points (Fig. 2).
Cadaveric LT for patients with MELD score < 18 were performed
exceptionally during the study period.
Impact of MELD-based allocation system on
probability to be transplanted
Adult elective patients had a median waiting list time of 155 days
with an overall accessibility to decease donor LT of 41% (Table 1).
As expected, the median waiting time increased inversely with the
MELD score reaching a median time of 440 days for the group
with <10 points (Fig. 3).
To assess the impact of the ‘real MELD score’ on waiting list
mortality and on probability to be transplanted, 141 patients were
excluded who had awarded points by the MELD exception Experts
Committee. The probability of receiving a cadaveric LT positively
correlated with the calculated MELD score with higher chances to
be transplanted in the highest MELD score subgroups (Fig. 4).
With scores 18′ the probability of receiving a liver remained
greater than 50%. The largest MELD subgroup with <10 points
(n = 433) had the lower probability of being transplanted with a
decease donor LT (3%) among all subgroups of elective patients.
Surprisingly, the subgroup of patients with extra-points because
of T2 HCC had the highest probability to be transplanted (94/111,
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84.6%) compared with all others subgroups of MELD score cat-
egories, and even higher compared with other patients without
cancer but stratified in the same subgroup with a MELD score
22–25 (72.9%, P < 0.03).
The number of adult live donor LT performed during the
MELD era was extremely low representing only 15/680 (2.2%) of
LT performed for elective candidates. Adult live LT was only per-
formed electively in patients with low MELD scores (median 8,
range 6–15).
Impact of the MELD-based allocation system on
waiting list mortality
For elective candidates, the overall mortality rate during the
MELD era was higher compared with the pre-MELD period
(Table 2). While the mortality in patients under the emergency
status remained equal over both periods, the mortality rate in
elective candidates increased significantly from 10.4% in the pre-
MELD to 14.8% in the MELD era. As expected, the mortality rate
during the MELD era in emergency patients was significantly
higher compared with elective patients (24.7% vs. 14.8%,
P < 0.002).
When elective patients stratified by ‘real MELD score’
(n = 1482) were grouped by MELD score, patient deaths were
more frequent in those subgroups with MELD < 18 points. The
highest number of deaths was present in the subgroup with
MELD < 10 points (Fig. 5). In this cohort of elective patients, the
absolute number of deaths in each subgroup of MELD score was
mainly equal on the early phase after listed (i.e. within the first 3
months) but this number increased within the first year for
patients with a MELD score below 18 (Fig. 6).
When the probability of being transplanted was compared with
the probability of dying waiting for a liver, the subgroups with
Table 1 Characteristics and reasons for removal from the waiting list grouped by category of the cohort of adult LT candidates in Argentina
during the study period (n = 1773)
Elective status Emergency status Total
Number of cases (%) 1623 (72) 150 (28) 1773 (100)
Age (years) 53.7 (18–74)a 44.1 (18–70)a 53.1 (18–74)
Gender (M/F) 926/697a 54/96a 980/793
Waiting list time (days)b 155 (40–519) 4.5 (3–8.2) 125 (25–477)
Cadaveric donor LT (%) 665 (41) 95 (63.3) 760 (42.9)
Live donor LT (%) 15 (0.9) 1 (0.7) 16 (0.9)
Deaths (%) 240 (14.8) 37 (24.7) 277 (15.6)
Drop-out from the listc (%) 46 (2.8) 4 (2.6) 51 (2.8)
Improved of clinical situation (%) 19 (1.2) 10 (6.7) 29 (1.6)
Data expressed as median and range or interquartile range (IQR) when indicated.
aP < 0.001.
bMedian and interquartile range.
cDrop-out from the waiting list because of infection, poor overall status, neurological disorders or tumour progression.
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Figure 2 Distribution of the number of cadaveric donor liver transplantations performed according to each model of end-stage liver disease
(MELD) subgroup in a cohort of 1623 adult elective candidates in Argentina
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18 points were more likely to be transplanted (Fig. 4). In con-
trast, patients with <18 points had a higher probability of dying
waiting for the liver compared with the probability to be trans-
planted with a cadaveric liver donor (16.2% vs. 10%; P < 0.01).
Patients with <10 MELD points had more than a fourfold prob-
ability of dying on the waiting list than of being transplanted
(14.3% vs. 3%; P < 0.0001). Among the subgroup with a MELD
score 22–25, the mortality was lower in patients with extra-points
as a result of early stage HCC (6/111, 5.4%) compared with other
patients without cancer (19/131, 11.5%) but not significantly.
‘Real MELD score’ patients (=1482) were stratified based on
aetiology of the liver disease and those patients with extra-MELD
points as a result T2 HCC (=111) were analysed as an independent
subgroup without considering the aetiology of the underlying
liver disease (Fig. 7). Mortality was significantly lower in the sub-
group with T2 HCC compared with all other elective patients
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Table 2 Deaths and mortality rate (%) on the waiting list of adult patients listed for liver transplantation in Argentina in two periods: pre-MELD
(n = 659) and MELD era (n = 1773)
Period Pre- MELD era (2004) MELD era (2005–2009) P value
Global (%) 78/659 (12) 277/1773 (15.6) <0.02
Emergency status (%) 18/77 (23.3) 37/150 (24.7) <0.95
Elective status (%) 61/582 (10) 240/1623 (14.8) <0.01
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without cancer (5.4% vs. 15.8%, P < 0.05) and compared with
several subgroups of patients having specific underlying benign
disorders such as hepatitis C virus infection (P < 0.01), cholestatic
liver disease (P < 0.02), cryptogenic cirrhosis (P < 0.02), alcoholic
abuse (P < 0.02) or autoimmune hepatitis (P < 0.01).
Discussion
The MELD-based allocation policy was adopted with the primary
goal of achieving a significant reduction in waiting list mortality.
In contrast with the reported experience in US, the implementa-
tion of this new allocation system in Argentina led to a significant
increment on waiting list mortality compared with the pre-MELD
era.1,17 As expected, the new ‘sickest first’ policy resulted in most
cadaveric donor LT being performed in patients with a high
MELD score. In contrast with the North American experience,
patient deaths on the waiting list occurred more frequently in low
MELD candidates (i.e. <10 MELD points) who had the lowest
probability to be transplanted and more than a fourfold risk of
dying waiting for a liver. The subgroup of patients with T2 HCC
benefited most with the lower mortality rate and the highest
probability of being transplanted using a cadaveric donor organ.
Therefore, an intense review process is urgently needed to main-
tain equity and justice of access to the limited donor pool of
cadaveric liver organs available.
The implementation of the MELD-based allocation policy by
the US has triggered continuous re-examination of its efficiency
for measuring severity of liver disease and its utility for prioritiz-
ing candidates for LT. However, to the best of our knowledge, this
is the first analysis of patients listed for LT under the MELD
system that is not based on the United National Organ Sharing
database. Therefore, the major strength from our study is that a
large national cohort of patients was used for a period of almost 4
years with the intention of validating this new model outside US.
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Although our experience was not in line with the previously
reported experience from North America, we have to accept that
the MELD system dramatically improved organ allocation in
comparison with the previous subjective system that emphasized
time on the waiting list as the main variable for liver allocation.
Particularly in Argentina, many reasons motivated that we con-
sider the implementation of the MELD policy as an important
‘step forward’ in organ allocation. First, the INCUCAI was forced
to create a modern centralized electronic database for collecting
data from each patient listed in the national waiting list. Second, as
the MELD score is based on the results of three readily available,
objective and easily reproducible laboratory tests, logistics in each
LT centre were facilitated. Third, the MELD system provided
transparency in the allocation system and this fact will permit a
continuous reviewing process to ensure equity and justice in
organ allocation.
Our national centralized database has many limitations that
could jeopardize the quality of our study. First, the use of a
national database poses recognized limitations. Changes in the
database, recording systems and/or personnel during the study
period may affect data quality.18 Missing data and erroneously
recorded data could also affect the validity of the results. Second,
it analyses the patient’s MELD score at a given point in time (i.e.
at the time of allocation, drop-out, death or the most recent)
without considering the initial MELD score at the time of listing.
Therefore, an analysis of the accuracy of variation in MELD score
for predicting mortality in the waiting list cannot be performed.
Third, as donor variables were not matched for each patient in
the central database, further studies investigating allocation of
marginal organs in high or low MELD patients cannot be
performed.19,20 Finally, post-operative outcome and long-term
survival are not prospectively recorded by the INCUCAI so far
and, unfortunately, the survival benefit of the MELD-base alloca-
tion policy is unpredictable in Argentina. Consequently, after this
first comprehensive analysis of this new national database, donor
characteristics must be recorded as well as each patient outcome
after transplantation. Continuous analyses using other national
databases are urgently needed to better evaluate and continuously
validate the MELD-based allocation system in each country indi-
vidually to guaranty transplantation utility and equity worldwide.
Many variables could eventually increase LT waiting list mor-
tality including a low donation rate, a low number of cadaveric
and live donor LT, a growing gap between the number of patients
listed and the number of transplants and finally, an inadequate
allocation system directing liver grafts to candidates in good clini-
cal conditions. For example, the implementation of the MELD-
based policy in the US was associated with an overall decline in
waiting list mortality and time to transplantation.1,18 However, the
2005 Organ Procurement and Transplantation Network annual
report reveals that the mortality has been declining since 1995 and
in fact remained relatively flat after 2002.21 This steady decline in
death rate despite an increase in the number of patients on the
waiting list was attributed to a 34% increase in the number
of transplantations performed since 1999, independent of any
impact that the MELD implementation had.21 The experience in
Argentina revealed that even in the presence of encouraging sta-
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tistics including a higher overall and multi-organic donation rate,
an increment in the number of LT and a decreasing gap between
the number of patients on the waiting list and number of deceased
donor LT; the adoption of the MELD allocation system resulted in
a higher mortality rate on the waiting list but only for elective
candidates. Mortality on the waiting list for patients listed under
emergency conditions who are not influenced by this new policy
remained stable after MELD system adoption. As the variable
‘cause of death’ is not included in our prospective national data-
base, we failed to provide this information in the present study.
However, we can state that the absolute number of deaths
increased considerably within the first year for patients with a
MELD score below 18 probably because of the fact that they had
a very low accessibility to LT in contrast with an easy access of
‘sickest’ candidates with MELD score 22 points. Perhaps we can
speculate that socio-economical factors and differences in the US
and the Argentinean health systems (e.g. regional vs. national
allocation system, lack of homogeneous distribution of LT centres
among the country, larger geographical distances from patient
location to LT center, etc.) are the surrogate factors impairing
patient survival on the waiting list in Argentina. Further investi-
gation focused on causes rather than number of deaths on the
waiting list in both countries will help to clarify these contradic-
tory experiences.
We should acknowledge the constant efforts reflected in many
studies in developing a better prognostic scoring system for cir-
rhotic patients to improve equity and utility of LT. However,
several criticisms could be raised against the MELD allocation
system. Some subjective clinical situations such as patients with
intractable pruritus, encephalopathy, refractory ascites or recur-
rent bacterial cholangitis should better qualify for LT regardless of
a low MELD score.22 Other authors suggested that serum sodium
values that are deteriorating in patients with refractory ascites or
hepatorenal syndrome should be added to the MELD score to
better assess transplant need.23,24 Moreover, variability between
laboratory methods in determination of the INR and those
patients requiring anticoagulants could falsely increase the MELD
score overestimating the overall severity of the liver disease.25
Finally, although the MELD score proved to be a robust marker of
early mortality across a wide spectrum of causes of cirrhosis,
patients with cholestatic diseases such as primary and secondary
biliary cirrhosis are still underestimated. In our cohort of adult
elective patients, those having cholestatic cirrhosis had the highest
mortality rate compared with other aetiologies. Perhaps, to over-
come this problem, the weight of the bilirubin level in the
mathematical formula of MELD score could be increased to com-
pensate this undesirable situation.
An important finding of our study is that patients with pre-
sumed T2 stage HCC benefit excessively from the MELD exception
resolution. This subgroup benefited from the greater access to
cadaveric donor LT, a depreciable drop-out rate for tumour pro-
gression and the lowest mortality rate compared with other sub-
groups of patients stratified according to their MELD scores on
the waiting list. Moreover, patients with presumed T2 stage HCC
regardless of the underlying liver disease had the lowest mortality
rate on the waiting list compared with other patients without
cancer. In this scenario, the best notice for a cirrhotic patient listed
for LT is that a new nodule that fulfills the non-invasive criteria for
diagnosis of T2 stage HCC was detected. Surprisingly, patients
with T2 HCC had the highest probability to be transplanted
compared with other MELD score subgroups, and even among
patients with a MELD score of 22–25 but without cancer. Sur-
geons may prefer to transplant patients with HCC rather than
patients with benign disorders. Clearly, this ‘fast track LT’ with a
short waiting time for patients with T2 HCC motivated a signifi-
cant reduction on adult live donor LT application in Argentina as
compared with the pre-MELD era. During the MELD era, only a
few adult live donor LTs were performed and none in patients with
T2 HCC. To provide equity in the allocation system, these data
raise the question as to whether the priority points of patients
with T2 HCC should be reduced. Further multidisciplinary dis-
cussion is urgently needed to discuss how to allocate fairly, cadav-
eric donor livers without compromising patient survival of
patients without early stage liver cancer who were listed for LT in
Argentina.
Finally, the survival benefit of the MELD-based allocation
system has been validated only in US.1 A negative survival benefit
has been demonstrated for candidates with MELD scores below
15.17 Current controversy is whether the national liver allocation
policy in the US should disallow LT for those patients listed with
low MELD scores.26 Clearly, the North American experience
cannot be extrapolated to other countries such as Argentina where
most patients are dying with a low MELD score but requiring a LT.
Probably, the most important conclusion that arises from this
study relies on the fact that the MELD-based allocation system is
not a ‘copy and paste’ policy that should be automatically adopted
for all countries worldwide. Perhaps many financial, logistic and
structural limitations existing in developing countries that moti-
vated validation of the reported experience in North America was
not feasible in our country. Probably, some modifications to the
MELD system are required and maximum efforts should be done
to properly adapt this novel and promising policy to the local
situation of each country.
Conclusions
The new MELD-based allocation system has been successfully
adopted in Argentina. However, after its implementation, the
mortality rate of elective patients on the waiting list increased and
most patients are dying with a low MELD score. Patients with T2
HCC are excessively benefiting from additional points of MELD
jeopardizing the principle of justice and equity in allocation of
cadaveric donor liver grafts. A comprehensive revision of the
impact of the MELD-based allocation system on the waiting list
must be performed in each new country adopting this novel strat-
egy. The re-estimation of the risk of dying contrasted to the prob-
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ability to be transplanted must be performed individually in every
country for every patient listed for LT according to their MELD
score. Further investigations focused on the strict analysis of spe-
cific variables including cultural, logistic and socio-economical
factors inherent to developing and developed countries would
help in optimizing the principles of justice and equity in each
country individually.
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